This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
May 26, 2022
Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting
May 18, 2022
BONESUPPORT receives market authorization for CERAMENT G in the US
May 16, 2022
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
May 16, 2022
Q1 2022 General Market Overview
May 12, 2022
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
May 12, 2022
Targovax ASA: First quarter 2022 results
May 11, 2022
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease
May 11, 2022
Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial
May 11, 2022
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events